secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2025-02-19T23:59:59+00:00
Accession:  0001127537-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx reports record Q4 revenue $23.8M (+23% YoY) and FY2024 revenue $83.8M (+22%); FY2025 guidance $96-98M
--------------------------------------------------------------------------------

- Record Q4 2024 worldwide revenue $23.8M, up 23% YoY; U.S. revenue $15.9M (+16%), international $7.9M (+42%).
- Full year 2024 revenue $83.8M, up 22% YoY; net loss $56.4M ($1.44/shr) narrowed from $60.8M ($1.60/shr) in 2023.
- Adjusted EBITDA loss improved to $31.3M in 2024 from $39.0M in 2023; gross margin stable at 74%.
- Cash and equivalents $101.5M at year-end 2024; added 11 new U.S. Zephyr Valve treatment centers in Q4.
- FY2025 revenue guidance $96-98M (15-17% growth); operating expenses $133-135M including $22M stock comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000003/0001127537-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000003/lung-20250219.htm
  HTML page:      https://secwatch.observer/filing/0001127537-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer